Business briefs: Roche, Gilead

Share this article:

An anonymous complaint to UK industry self-policing arm PCMPA (Prescription Medicines Code of Practice Authority) alleges Roche employees behaved inappropriately while attending an overseas medical conference. The complainant alleged that “two very senior Roche personnel” supplied round after round of shots to a delegation of doctors, and that the alcohol “flowed like hot lava, unstoppably.” Roche responded that “Staff did not go to the bar with any health professionals nor did they arrange to meet any.” The panel found no evidence that the Roche staffers “had provided any hospitality to UK health professionals as alleged” and so found no violation.

In Gilead's Q4 earnings call, CFO Robin Washington said intellectual property for its new hepatitis C compound “is domiciled in Ireland,” which, The Wall Street Journal reported, could effectively cut Gilead's tax rate to by 5-7%, due to an Irish policy which exempts income from taxes on patent royalties. With analysts forecasting worldwide sales of $7 billion a year for Gilead – this off-shore move could mean an additional $500 million a year in profit for blockbuster hopeful sofosbuvir (AKA PSI-7977). The AIDS Healthcare Foundation labeled Gilead a “tax-supported tax evader.” AHF president Michael Weinstein roared: “This latest move should come as no surprise as Gilead has continually pursed price hikes and exploited patent loopholes to maximize earnings on its lifesaving HIV/AIDS Drugs … by charging government-funded programs exorbitantly high prices that limit access.”           

Share this article:

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.